Rejuvenation Technologies Inc.

Summer 2018Active

mRNA therapeutics to extend healthspan entering clinical trials

Save

Summer 2018Active

mRNA therapeutics to extend healthspan entering clinical trials

Save

Company details

Stanford-patented essential drug platform unlocks the healthspan, which is limited by short telomeres. Reverses 10 years of telomere shortening with a single dose. Preclinical efficacy in fibrotic liver and lung disease. Entering IND-enabling. 50+ granted patents, 7 patent families. FDA INTERACT cleared.

Location

San Francisco, CA, USA

Founded

Unknown

Request the Rejuvenation Technologies Inc. report.

Rejuvenation Technologies Inc. has no report yet. Sign in with your email to request one.